Study summary
Adding immunotherapy to chemo after surgery cut recurrence in dMMR stage III colon cancer
86.3%free of cancer at 3 years, vs 76.2% with FOLFOX alone
What was tested
Atezolizumab plus FOLFOX chemotherapy against FOLFOX alone after surgery for stage III colon cancer with mismatch repair deficiency (dMMR, about 1 in 7 colon cancers).
What they found
- 3-year disease-free survival was 86.3% vs 76.2%.
- Severe side effects were more common (84.1% vs 71.9%).
What it means
Makes immunotherapy part of treatment after surgery for dMMR stage III colon cancer.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.